Drugs / Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04825223 Comparator | Mar 2021 → Jul 2022 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04825223 ↗ |
| Modality | Vaccine | “Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)” NCT04825223 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04825223 ↗ |